OncoArendi Therapeutics as Platform-based Polish Biotech Company – A Case Study

Author(s): Marcin Szumowski*

Journal Name: Technology Transfer and Entrepreneurship

Volume 7 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

OncoArendi Therapeutics SA (OAT) has been founded in 2012 as USstyle biotech operating in Poland. From the beginning, OAT has been focused on first-in-class or best-in-class programs involving interactions with novel targets with no clinical validation. The experienced group of founders thought that Poland offered an abundance of young talent and non-dilutive financing from European and national grants and subsidies, newly established research infrastructure and relatively little competition, as the biotech sector was still in its infancy. With strong proprietary IP, they thought, an experienced group of medicinal chemists could launch a competitive small molecule discovery business. Furthermore, the net cost of developing small molecules in Poland was several-fold lower than in the US or in western European countries. Based on these competitive factors, one could develop several programs in parallel with limited private investment, thus diversifying the high scientific and technological risk and increasing chances of long-term success. This case study shows how this strategy played out for OncoArendi over the last 7 years and how OncoArendi positions itself within the Polish biotech sector and on the increasingly competitive global biopharmaceutical scene.

Keywords: Oncology, inflammation, biotechnology, small molecules, Poland, OncoArendi.

[1]
Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304(5677): 1678-82.
[http://dx.doi.org/10.1126/science.1095336] [PMID: 15192232]
[2]
Lipner J, Lissy M, Dymek B, et al. Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases. Eur Respir J 2018; 52(Suppl. 62). PA5228
[3]
Van Dyken SJ, Locksley RM. Chitins and chitinase activity in airway diseases. J Allergy Clin Immunol 2018; 142(2): 364-9.
[http://dx.doi.org/10.1016/j.jaci.2018.06.017] [PMID: 29959948]
[4]
Cho SJ, Weiden MD, Lee CG. Chitotriosidase in the pathogenesis of inflammation, interstitial lung diseases and COPD. Allergy Asthma Immunol Res 2015; 7(1): 14-21.
[http://dx.doi.org/10.4168/aair.2015.7.1.14] [PMID: 25553258]
[5]
Dymek B, Sklepkiewicz P, Mlacki M, et al. CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis. Eur Respir J 2018; 52(Suppl. 62). OA5361
[6]
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun 2019; 10(1): 3000.
[http://dx.doi.org/10.1038/s41467-019-10979-3] [PMID: 31278254]
[7]
Grzybowski M, Stańczak PS, Pęczkowicz-Szyszka J, Wolska P, Zdziarska ZM, Mazurkiewicz M. Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors. Annals of Oncology 2017; 28(Suppl. 11) mdx711.052


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 1
Year: 2020
Page: [74 - 84]
Pages: 11
DOI: 10.2174/2213809907999200330164359
Price: $25

Article Metrics

PDF: 6
HTML: 1